课题基金 / 基金详情

Comparative genetic and proteomic analysis of late-outgrowth endothelial progenitor cells from pulmonary arterial hypertension patients bearing mutations in bone morphogenetic protein receptor type II

Comparative genetic and proteomic analysis of late-outgrowth endothelial progenitor cells from pulmonary arterial hypertension patients bearing mutations in bone morphogenetic protein receptor type II
骨形态发生蛋白受体 II 型突变的肺动脉高压患者晚期生长内皮祖细胞的比较遗传和蛋白质组学分析
批准号：
203286
负责人：
Ormiston Mark L
金额：
$10.93万
依托单位：
University of Cambridge (UK)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-02-01 至 2013-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=203286&lang=en
关键词：
Bone Morphogenetic Protein 9 Bone Morphogenetic Protein Receptor Type Ii Endothelial Cells Endothelial Progenitor Cells Pulmonary Arterial Hypertension

项目摘要

项目成果

Ormiston Mark L的其他基金

相似基金

相关文献

中文摘要
翻译
肺动脉高压(PAH)是一种导致肺内血管变窄和丧失的疾病，导致心脏应激增加，最终死于心力衰竭。目前还没有有效的治疗方法来治疗这种疾病。
英文摘要
Pulmonary arterial hypertension (PAH) is a disease that causes a narrowing and loss of the blood vessels in the lung, leading to increased stress on the heart and eventual death by heart failure. There are currently no effective treatments for this devast
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Examining the role for natural killer cell TGFb signaling in pulmonary vascular development and the pathogenesis of pulmonary hypertension
Targeting bone morphogenetic protein-9 as an angioproliferative switch in pulmonary arterial hypertension
Canada Research Chairs - Tier 2
Cellular and molecular mechanisms of Natural Killer cell-mediated vascular remodeling in pulmonary arterial hypertension
海外基金